Navigation Links
MultiVu Video Feed: Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna(R) Reduces Key Marker of Kidney Disease
Date:6/4/2008

Diabetes and high blood pressure are the leading causes of kidney disease, which affects approximately 26 million people in the United States. For patients with high blood pressure and type 2 diabetes, reducing proteinuria is associated with slowing the progression of kidney disease, which can reduce the risk of kidney failure. There are approximately 14 million adults in the US diagnosed with diabetes and high blood pressure.

Data published in this week's New England Journal of Medicine demonstrate that the first direct renin inhibitor Tekturna (aliskiren), when added to the maximum dose of the angiotensin-receptor-blocker (ARB) losartan, reduced proteinuria, a key indicator of kidney disease, independent of its already proven ability to provide powerful blood pressure reductions. Damage to the kidneys caused by diabetes is the leading cause of end-stage renal disease in developed countries, affecting more than 1.5 million people worldwide.

In the AVOID (Aliskiren in the EValuation of PrOteinuria In Diabetes) study, Tekturna, when added to the maximum dose of losartan, reduced proteinuria by 20% compared to losartan alone in patients diagnosed with high blood pressure and type 2 diabetes. These patients were initially treated with the maximum dose of losartan, which has been shown to slow the progression of diabetic kidney disease.

Tekturna, the latest type of high blood pressure medication, works differently from other high blood pressure medications by targeting renin, an enzyme that starts a process that when inappropriately activated may lead to high blood pressure.

About Tekturna

Tekturna is a prescription medication for adults, used to treat high blood pressure. It can be used alone or in combination with other high blood pressure medications. Tekturna has not been adequately studied in combination with the maximum doses of a class of medications called ACE inhibitors.

Important Considerations:

IMPORTANT WARNING: If you get pregnant, stop taking Tekturna and call your doctor right away. Tekturna may harm an unborn baby, causing injury and even death. If you plan to become pregnant, talk to your doctor about other treatment options before taking Tekturna.

Do not take Tekturna if you are allergic to any of its ingredients. If you develop an allergic reaction involving swelling of the face, lips, throat and/or tongue which may cause difficulty in breathing and swallowing stop taking Tekturna and contact your doctor immediately.

Your blood pressure may get too low if you also take water pills, are on a low-salt diet, get dialysis treatments, have heart problems, or get sick with vomiting or diarrhea. Lie down if you feel dizzy or faint. Call your doctor right away.

Tell your doctor about all your medical conditions, including whether you are pregnant or plan to become pregnant, are breast-feeding, or have kidney problems.

In clinical studies, the most common side effect experienced by more patients taking Tekturna than patients taking a sugar pill was diarrhea. Other less common reactions to Tekturna include cough and rash.
For more information about Tekturna go to http://www.tekturna.com

SATELLITE FEED:

Thursday, June 5th, 2008

1:00 PM - 1:15 PM ET

Galaxy 26

C-Band

Transponder 24

Downlink Freq. 4180 Horizontal

NEWS: Study In Nejm Shows High Blood Pressure Drug Reduces Key Marker of Kidney Disease

FORMAT: B-roll and Soundbites

ADDITIONAL RESOURCES: Video, contact information and more available at: http://www.prnewswire.com/broadcast/33259/press.html

SOUNDBITES:

* Norman K. Hollenberg, M.D., Ph.D., Brigham and Women's Hospital, AVOID

study author

* Matthew Weir, M.D., University of Maryland Hospital, Director of the

Division of Nephrology and Clinical Research Unit

B-ROLL INCLUDES:

* Tekturna Mechanism of Action Animation; Tekturna Manufacturing Footage;

Patient/Doctor Footage

VIDEO PROVIDED BY: Novartis Pharmaceuticals Corporation

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3


'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MultiVu Video Feed: FREE NICOTINE REPLACEMENT THERAPY (NRT) TO BE OFFERED TO REGISTERED PILOTS INTERESTED IN QUITTING RELIEF IN LIGHT OF RECENT FAA RULINGS
2. MultiVu Video Feed: Richard Simmons and Ocean Spray Team-Up to Solve
3. MultiVu Video Feed: Podiatrists Keep America Walking
4. MultiVu Video Feed: Stinky Sneakers Worth Big Money!
5. MultiVu Video Feed: New National Colorectal Cancer Screening Guidelines Issued by the American Cancer Society
6. MultiVu Video Feed: LIFE AND STYLE EXPERT SANDRA LEE OFFERS RECIPES AND SHORTCUTS IN THE KITCHEN TO PEOPLE WITH RHEUMATOID ARTHRITIS
7. MultiVu Video Feed: WELCHOL (R) (COLESEVELAM HCL) RECEIVES FDA APPROVAL FOR GLUCOSE CONTROL IN ADULTS WITH TYPE 2 DIABETES MELITUS
8. Photo: MultiVu Promotes George DeTorres to Divisional Vice President for the MultiVu Healthcare Team
9. MultiVu Video Feed: NEW SURVEY FINDS THAT HALF OF CAREGIVERS SPEND 10 PERCENT OF THEIR INCOME CARING FOR AN OLDER LOVED ONE
10. MultiVu Video Feed: STARLIGHT STARBRIGHT UNVEILS GET FIT, GET RIGHT A PROGRAM TO PREVENT TYPE 2 DIABETES AND WEIGHT-RELATED CONDITIONS IN TEENS
11. MultiVu Video Feed: Parents of Kids With Infectious Diseases Sounds Alarm About the Dangers of Pertussis With "Silence the Sounds of Pertussis" Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... ... human health, today GrassrootsHealth, a public health promotion and research organization, declared May ... a technology-driven society, and other shifts in cultural behavior over the past several ...
(Date:5/4/2016)... ... May 05, 2016 , ... The talus is the part ... like falls, or traffic accidents can cause the talus bone to be fractured, and ... bone. In a first-of-its-kind procedure using 3D printing technology, internationally renowned orthopedic surgeon ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... donated 100 of its innovative kicking trainers to St. Jude Children’s Research Hospital ... is a durable, lightweight rubber band designed to teach children how to kick ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... Camas and Vancouver, WA, has announced the latest beneficiary of their ongoing ... Foundation and their Mammography Program, which provides free mammograms and diagnostic breast ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... products, announced today the introduction of the innovative newly improved Iso-Hip Wrap. ... replacement patients. The plush design enhances comfort and enables the patient to enjoy ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... DUBLIN , May 5, 2016 ... Markets has announced the addition of the  ... Highlights - 2016"  report to their ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The latest ... Landscape Highlights - 2016, provides comprehensive ...
(Date:5/5/2016)... , May 5, 2016 ... the addition of the  "Europe Thrombocytopenia ... 2016"  report to their offering.  ... ) , ,The latest research Europe ... - 2016, provides comprehensive insights into ...
(Date:5/5/2016)... , May 5, 2016 ... addition of the  "Europe Thalassaemia Market and ... their offering.       (Logo: ... Europe Thalassaemia Market and Competitive Landscape Highlights ... pipeline products, Thalassaemia epidemiology, Thalassaemia market valuations ...
Breaking Medicine Technology: